TORONTO, March 7 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc. (TSX:SDI) today announced its operational highlights and financial results for the fiscal year ended December 31, 2007.
"Spectral's priority is the commercialization of its EAA(TM) Endotoxin
Activity Assay, the only FDA cleared assay for the measurement of
endotoxin. Endotoxemia is a systemic response to bacterial toxins that can
rapidly lead to organ dysfunction, septic shock and ultimately death.
Healthcare professionals have become much more aware of endotoxemia over
the last several years, and many of the emerging therapies for sepsis now
advancing though clinical trials target endotoxin," said Dr. Paul Walker,
President and CEO of Spectral Diagnostics. "The growing awareness of
endotoxemia, and the increasing number of therapies being developed for
this indication, position us well to drive adoption of the EAA(TM), which
can be used to identify patients, enable therapeutics and monitor
Highlights from 2007:
- Entered into an exclusive agreement in November 2007 with Toray
Medical Co. Ltd. to distribute Spectral's EAA(TM) Endotoxin Activity
Assay in Japan. Toray Medical will market and sell the EAA(TM) in
conjunction with its Toraymyxin blood purification device, which
removes endotoxin from the bloodstream. Toray Medical will also
distribute the EAA(TM) diagnostic as a stand-alone product.
- Launched the EAA(TM) in Germany in September 2007 through A. Menarini
Diagnostics Deutschland, building on a distribution agreement signed
in May 2007 which covers Germany and includes an option to extend the
arrangement to the rest of Europe.
- Expanded its EAA(TM) product distribution agreement in Italy with its
partner Estor, SpA in May 2007. The expanded agreement is aimed at
increasing the number of hospitals in Italy utilizing the EAA(TM)
|SOURCE Spectral Diagnostics Inc.|
Copyright©2008 PR Newswire.
All rights reserved